SCHEMBL854928

SCHEMBL854928

Cc1ccc(NCc2ccc(N(C)C)cc2)cc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.62
NPC1 O15118 6/20 0.62
RAB9A P51151 5/20 0.62
LMNA P02545 4/20 0.62
L3MBTL1 Q9Y468 4/20 0.62
CYP1A2 P05177 2/20 0.62
CYP2D6 P10635 2/20 0.62
CYP2C9 P11712 2/20 0.62
CYP2C19 P33261 2/20 0.62
CYP3A4 P08684 1/20 0.62
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
ALDH1A1 P00352 6/20 0.53
TDP1 Q9NUW8 4/20 0.53
HTT P42858 4/20 0.53
GFER P55789 3/20 0.53
KMT2A Q03164 3/20 0.53
GAA P10253 3/20 0.51
KDM4E B2RXH2 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6376196 0.86 CA1 (0.54) MAPTNPC1RAB9ALMNAL3MBTL1
SCHEMBL856237 0.84 CA1 (0.70) MAPTNPC1RAB9ALMNAL3MBTL1
SCHEMBL29868445 0.82 MAPT (0.70) MAPTNPC1RAB9ALMNAL3MBTL1
SCHEMBL855759 0.81 ALDH1A1 (0.62) MAPTNPC1RAB9ALMNAL3MBTL1
SCHEMBL16846471 0.79 CA1 (0.60) MAPTNPC1RAB9ALMNAL3MBTL1
SCHEMBL11176623 0.79 MAPT (0.65) MAPTNPC1RAB9ALMNAL3MBTL1
SCHEMBL856263 0.79 CA1 (0.52) MAPTNPC1RAB9ALMNAL3MBTL1
SCHEMBL17813061 0.78 INSR (0.57) MAPTNPC1RAB9ALMNAL3MBTL1
SCHEMBL855663 0.77 ALDH1A1 (0.64) MAPTNPC1RAB9ALMNAL3MBTL1
SCHEMBL855107 0.76 CA1 (0.60) MAPTNPC1RAB9ALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1308438-B9 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-28 EP disclosed
EP-1308438-B1 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2010-10-20 EP disclosed
US-7105567-B2 3-substituted urea derivatives and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-09-12 US disclosed
US-20030207939-A1 Novel 3-substituted urea derivatives and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2003-11-06 US disclosed
EP-1308438-A1 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207939-A1 Novel 3-substituted urea derivatives and medicinal use thereof C5AR1, C5AR2, C3AR1 MAPT 205/4885NPC1 2296/4885RAB9A 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.